| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/27/2023 | 58.06% | Morgan Stanley | $41 → $45 | Maintains | Overweight |
| 10/12/2023 | 44.01% | Morgan Stanley | $42 → $41 | Maintains | Overweight |
| 10/10/2023 | 75.62% | JMP Securities | $53 → $50 | Maintains | Market Outperform |
| 10/03/2023 | 12.4% | UBS | $37 → $32 | Maintains | Neutral |
| 09/26/2023 | 47.52% | Morgan Stanley | $44 → $42 | Maintains | Overweight |
| 09/19/2023 | 12.4% | Goldman Sachs | $37 → $32 | Downgrades | Neutral → Sell |
| 07/31/2023 | 29.96% | UBS | $32 → $37 | Maintains | Neutral |
| 07/14/2023 | 51.04% | Morgan Stanley | $43 → $43 | Reiterates | Overweight → Overweight |
| 07/13/2023 | — | Keefe, Bruyette & Woods | Upgrades | Underperform → Market Perform | |
| 07/12/2023 | 51.04% | Morgan Stanley | $36 → $43 | Upgrades | Equal-Weight → Overweight |
| 07/10/2023 | 86.16% | JMP Securities | → $53 | Reiterates | Market Outperform → Market Outperform |
| 07/03/2023 | — | Wolfe Research | Upgrades | Underperform → Peer Perform | |
| 05/22/2023 | 86.16% | JMP Securities | $53 → $53 | Reiterates | Market Outperform → Market Outperform |
| 05/01/2023 | 8.89% | Keefe, Bruyette & Woods | $34 → $31 | Maintains | Underperform |
| 04/12/2023 | 26.45% | Morgan Stanley | $29 → $36 | Upgrades | Underweight → Equal-Weight |
| 01/10/2023 | 86.16% | JMP Securities | $56 → $53 | Maintains | Market Outperform |
| 10/31/2022 | 1.86% | Morgan Stanley | $28 → $29 | Maintains | Underweight |
| 08/04/2022 | 26.45% | Goldman Sachs | $32 → $36 | Maintains | Neutral |
| 07/18/2022 | 5.37% | Morgan Stanley | $40 → $30 | Downgrades | Equal-Weight → Underweight |
| 07/13/2022 | 5.37% | Keefe, Bruyette & Woods | $38 → $30 | Downgrades | Market Perform → Underperform |
| 07/08/2022 | 54.55% | Piper Sandler | $45 → $44 | Maintains | Overweight |
| 04/07/2022 | 58.06% | Piper Sandler | $49 → $45 | Maintains | Overweight |
| 04/07/2022 | 96.7% | JMP Securities | $58 → $56 | Maintains | Market Outperform |
| 04/07/2022 | 36.99% | Wolfe Research | → $39 | Downgrades | Peer Perform → Underperform |
| 03/09/2022 | 82.65% | Piper Sandler | $62 → $52 | Maintains | Overweight |
| 03/08/2022 | 40.5% | Morgan Stanley | → $40 | Downgrades | Overweight → Equal-Weight |
| 02/04/2022 | 72.11% | Keefe, Bruyette & Woods | $52 → $49 | Downgrades | Outperform → Market Perform |
| 01/04/2022 | 51.04% | UBS | $47 → $43 | Maintains | Neutral |
| 12/08/2021 | 93.19% | Morgan Stanley | $61 → $55 | Maintains | Overweight |
| 10/01/2021 | 103.72% | Keefe, Bruyette & Woods | $53 → $58 | Upgrades | Market Perform → Outperform |
| 05/03/2021 | 72.11% | Credit Suisse | $50 → $49 | Maintains | Neutral |
| 04/12/2021 | 75.62% | Credit Suisse | $49 → $50 | Maintains | Neutral |
| 04/07/2021 | 114.26% | Morgan Stanley | → $61 | Upgrades | Equal-Weight → Overweight |
| 01/14/2021 | 75.62% | Keefe, Bruyette & Woods | → $50 | Downgrades | Outperform → Market Perform |
| 12/16/2020 | 72.11% | Seaport Global | → $49 | Initiates Coverage On | → Buy |
| 12/14/2020 | 82.65% | Morgan Stanley | $39 → $52 | Upgrades | Underweight → Equal-Weight |
| 10/12/2020 | 36.99% | Morgan Stanley | $29 → $39 | Maintains | Underweight |
| 10/09/2020 | 47.52% | JMP Securities | $40 → $42 | Maintains | Market Outperform |
| 08/03/2020 | 1.86% | Morgan Stanley | $28 → $29 | Maintains | Underweight |
| 08/03/2020 | 19.42% | Credit Suisse | $32 → $34 | Maintains | Neutral |
| 06/23/2020 | 12.4% | Credit Suisse | → $32 | Initiates Coverage On | → Neutral |
| 05/06/2020 | 22.94% | Argus Research | $51 → $35 | Maintains | Buy |
| 05/04/2020 | -15.7% | UBS | $23 → $24 | Maintains | Neutral |
| 05/01/2020 | -15.7% | CFRA | $22 → $24 | Maintains | Sell |
| 04/24/2020 | -22.73% | CFRA | $46 → $22 | Downgrades | Hold → Sell |
| 04/09/2020 | 40.5% | JMP Securities | $50 → $40 | Maintains | Market Outperform |
| 04/09/2020 | -1.65% | Morgan Stanley | $39 → $28 | Maintains | Underweight |
| 03/25/2020 | -19.21% | UBS | $41 → $23 | Maintains | Neutral |
| 01/31/2020 | 61.57% | CFRA | $43 → $46 | Maintains | Hold |
| 01/27/2020 | 68.6% | Keefe, Bruyette & Woods | $40 → $48 | Upgrades | Market Perform → Outperform |
| 01/13/2020 | 61.57% | Buckingham Research | $40 → $46 | Maintains | Neutral |
| 01/06/2020 | — | Wolfe Research | Upgrades | Underperform → Peer Perform | |
| 11/20/2019 | 22.94% | Morgan Stanley | → $35 | Initiates Coverage On | → Underweight |
| 10/09/2019 | 40.5% | Buckingham Research | $41 → $40 | Maintains | Neutral |
| 07/11/2019 | 44.01% | Buckingham Research | $45 → $41 | Maintains | Neutral |
| 06/10/2019 | — | UBS | Downgrades | Buy → Neutral | |
| 04/11/2019 | — | B of A Securities | Downgrades | Buy → Neutral | |
| 11/06/2018 | 61.57% | Goldman Sachs | → $46 | Initiates Coverage On | → Neutral |
What is the target price for Lazard (LAZ)?
The latest price target for Lazard (NYSE: LAZ) was reported by Morgan Stanley on October 27, 2023. The analyst firm set a price target for $45.00 expecting LAZ to rise to within 12 months (a possible 58.06% upside). 17 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Lazard (LAZ)?
The latest analyst rating for Lazard (NYSE: LAZ) was provided by Morgan Stanley, and Lazard maintained their overweight rating.
When is the next analyst rating going to be posted or updated for Lazard (LAZ)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Lazard, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Lazard was filed on October 27, 2023 so you should expect the next rating to be made available sometime around October 27, 2024.
Is the Analyst Rating Lazard (LAZ) correct?
While ratings are subjective and will change, the latest Lazard (LAZ) rating was a maintained with a price target of $41.00 to $45.00. The current price Lazard (LAZ) is trading at is $28.47, which is out of the analyst's predicted range.